All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
6 results for "Cancer" and "Gynecologic Cancers" and "Multiple Myeloma"
A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Subjects with Hematological Malignancies
Open-label, multiple-ascending dose study to evaluate the safety, PK, and preliminary clinical activity of KPG-818 as a single agent in adult subjects with selected hematological malignancies, except for multiple myeloma indication. KPG-818 will be used in combination with dexamethasone for dose escalation and dose expansion. The study will consist of 2 parts: Part 1 dose escalation and Part 2 dose expansion.
Protocol No
KANGPU-KPG-818-HEM-101
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma
JNJ-64407564 [anti-GPRC5DxCD3] is called a bispecific antibody because it has two arms that target a protein on the myeloma cells, GPRC5D, and a protein on T-cells, CD3. T-cells are a type of cell that can kill cancer cells. JNJ-64407564 [anti-GPRC5DxCD3] brings these killer T-cells to the myeloma cell resulting in myeloma cell death.
JNJ-64007957 [anti-BCMAxCD3] is called a bispecific antibody because it has two arms that target a protein on the myeloma cells, BCMA, and a protein on T-cells, CD3. T-cells are a type of cell that can kill cancer cells. JNJ-64007957 [anti-BCMAxCD3] brings ...
Protocol No
JANSSEN-64407564MMY1002
A Multicenter, Open-Label, Dose-Escalation Phase 1b Study Of AEVI-007 In Subjects With Relapsed Or Refractory Multiple Myeloma
AEVI-007,in the treatment of relapsed or refractory multiple myeloma.
Protocol No
AEVI-007-MM-101
A Phase I, Open-Label, Multicenter, Study of WVT078 in Subjects with Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to find the best dose of WVT078 or WVT078 combined with WHG626 that can be given to patients with multiple myeloma and to evaluate how well the treatment might work in treating patients with this type of cancer. This is the first time WVT078 or WVT078 combined with WHG626 are being used in humans. WHG626 has been studied previously in patients with different types of cancer than yours
Protocol No
NOVARTIS-CWVT078A12101
Sub Category
Phase 1/2 FIH Study of REGN5459 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to learn about the safety of REGN5459 and to find out what is the best dose of REGN5459 to give to patients with multiple myeloma. An additional purpose is to look for any signs that REGN5459 can treat your cancer.
Protocol No
REGENERON-R5459-ONC-1888
Sub Category
A Multi-Center, Open Label Phase 1/2 Study Of Cyt-0851, An Oral Rad51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
Protocol No
CYTEIR-CYT-0851-01-REFMAL639